Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Search of the Perfect Aortic Endograft

Executive Summary

The aortic endograft market stands out in the medical device arena for its rich history of failure. The number of products that have been pulled from the market or axed before they reached it exceeds the number of models currently available in the US. But despite these past failures, endovascular aortic procedures have thrived thanks to researchers’ tenacity. At this year's International Congress on Endovascular Interventions, top surgeons discussed a number of new devices and techniques aimed at widening the scope of endovascular aortic repair to a broader range of patients.

You may also be interested in...



Abingworth's Bet On Lombard: Best Of Both Worlds For VCs

As venture investing in medical devices continues to split between early- and late-stage deals, investors increasingly face a choice: early-stage deals, where valuations are low, but risk is high and timelines are generally long; and late-stage opportunities, where risk is lower and timelines shorter, but the valuations are much higher. What if you could find an opportunity with the timelines and risk profile of a late-stage deal, at the valuation of an early-stage deal? That's what investors at Abingworth believe they've found in Lombard Medical Technologies PLC, a company with a novel approach to endovascular abdominal aortic aneurysm repair.

EVAR Market: Challenges, Innovation and Growth

Endovascular aortic aneurysm repair procedures account for the majority of abdominal aortic aneurysm repairs performed in the US, and total worldwide revenues from aortic endograft systems now exceed $1 billion per year. Many believe that continuing improvements in endograft technology will drive EVAR penetration to 90% or beyond within the next five to 10 years. However, before that milestone is reached, the field must address a number of lingering concerns about long-term endograft stability and viability, and endograft systems will need to evolve to encompass a wider range of patients with challenging anatomy, including small or tortuous access vessels, short or highly angulated aortic necks, and aneurysms that lie close to the renal arteries.

Advancing The Technological Frontier In AAA Repair

Start-ups are striving to expand the patient pool for endovascular abdominal aortic aneurysm repair - and get in on one of the highest-growth device market opportunities. In this issue, we profile Altura Medical, Aptus Endosystems, Endoluminal Sciences and SOVAmed.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

MT035163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel